NCT01298128

NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment

A Randomized Controlled Trial of NuvaRing® Versus Combined Oral Contraceptive Pills for Pre-treatment in In-Vitro Fertilization (IVF) Cycles

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: University of Toronto · Academic / Other
• Sex: Female
• Age: 18 Years – 38 Years
• Healthy volunteers: Not accepted

Summary

The newly designed contraceptive ring, Nuvaring has a lower total steroid dose, and medications are delivered locally. It has been proven to be as safe and effective as the combined OCP in ovarian suppression and preventing ovulation with fewer side effects due to minimal systemic absorption. Following a single vaginal insertion, steroid concentrations remain stable for up to 4 weeks. It is hypothesized that Nuvaring may, therefore lead to better compliance, tolerability and acceptance by patients requiring ovarian suppression prior to COH for IVF.

Conditions

• Infertility
• In-vitro Fertilization

Interventions

Type	Name	Description
DRUG	NuvaRing	NuvaRIng 21 days for IVF pre-treatment.
DRUG	marvelon	marvelon 21 daily

Timeline

• Start date: 2006-02-01
• Primary completion: 2010-03-01
• Completion: 2010-12-01
• First posted: 2011-02-17
• Last updated: 2012-10-05
• Results posted: 2012-07-17